.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Argus Health
McKinsey
Cantor Fitzgerald
AstraZeneca
Cerilliant
QuintilesIMS
Express Scripts
Farmers Insurance
UBS

Generated: September 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 078217

« Back to Dashboard
NDA 078217 describes CARVEDILOL, which is a drug marketed by Zydus Pharms Usa Inc, Mylan, Lupin, Sandoz, Aurobindo Pharma, Pliva Hrvatska Doo, Sun Pharm Inds Inc, Dr Reddys Labs Ltd, Glenmark Generics, Apotex Inc, Teva, Cipla Ltd, Taro, Beximco Usa, Wockhardt Ltd, Hikma, and Sun Pharm Inds Ltd, and is included in seventeen NDAs. It is available from fifty suppliers. Additional details are available on the CARVEDILOL profile page.

The generic ingredient in CARVEDILOL is carvedilol. There are thirty-six drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the carvedilol profile page.

Summary for NDA: 078217

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength3.125MG
Approval Date:Sep 5, 2007TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength6.25MG
Approval Date:Sep 5, 2007TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength12.5MG
Approval Date:Sep 5, 2007TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Chubb
Mallinckrodt
Daiichi Sankyo
Cantor Fitzgerald
Moodys
Harvard Business School
Express Scripts
AstraZeneca
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot